Because of the risk of cytokine release syndrome (CRS) and neurologic toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), TECVAYLI® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TECVAYLI® and TALVEY® REMS. Healthcare facilities that dispense and administer TECVAYLI® must be enrolled and comply with the REMS requirements, including the healthcare professionals who prescribe, dispense, or administer TECVAYLI®. These facilities and healthcare professionals should be trained about the management of CRS and neurologic toxicities, including ICANS.
Consult with a TECVAYLI® prescribing physician if you have an eligible patient.
An eligible patient is assessed for treatment with TECVAYLI® by the treating physician at a Certified Treatment Center in consultation with the patient’s primary oncologist. TECVAYLI® availability is not guaranteed at the locations listed.
